EUVIMEDEUVIMED entdecken
Crossref

Alcohol Reduction and 15‐Year Cardiometabolic Changes in Glycemic, Lipid and Blood Pressure Profiles: A Target Trial Emulation Study

Takahiro Ichikawa iD, Hiroshi Okada iD, Shinta Yamamoto iD, Arata Sano, Yoshitaka Hashimoto, Kenya Kasahara, Hanako Nakajima iD, Masahide Hamaguchi iD, Hiroaki Murata, Kazushiro Kurogi, Eri Tsuda, Naoki Yoshida und 2 weitere

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11259-11269

DOI: 10.1111/dom.71335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.09.2026. Verfasst von Takahiro Ichikawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan. Hauptthemen laut MEDLINE: Blood Pressure, Blood Glucose, Alcohol Drinking, Lipids. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Novo Nordisk Pharma Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The long‐term cardiometabolic effects of alcohol reduction remain unclear. We evaluated the long‐term associations of sustained alcohol reduction with glycemic, blood pressure, and lipid profiles. Materials and Methods We conducted a pooled sequential target trial emulation using annual health examination data from Japanese employees (2008–2023). Eligible participants were aged ≥ 40 years and consumed ≥ 20 g/day of ethanol at baseline. Participants subsequently reducing alcohol intake to < 20 g/day formed the intervention group; those maintaining ≥ 20 g/day formed the control group. We applied inverse probability weighting to estimate the per‐protocol effect of sustained alcohol reduction. We used weighted generalized estimating equations to estimate longitudinal trajectories of fasting plasma glucose (FPG), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides, high‐density lipoprotein (HDL) cholesterol, and low‐density lipoprotein (LDL) cholesterol.

Results

Among 266 699 eligible trial entries, 30 280 and 229 946 trial entries were included in the intervention and control groups, respectively. Alcohol reduction was associated with persistently lower FPG, SBP, DBP, and triglycerides over 15 years. At Year 15, between‐group differences were −1.8 mg/dL for FPG, −3.4 mmHg for SBP, −2.2 mmHg for DBP and −20.4 mg/dL for triglycerides (all p ≤ 0.005). Conversely, HDL cholesterol levels were consistently lower and LDL cholesterol levels modestly higher in the intervention group. Blood pressure‐lowering effects were consistent across genders, and findings were broadly consistent across sensitivity, subgroup, and dose‐transition analyses.

Conclusions

Sustained alcohol reduction improved long‐term FPG, blood pressure, and triglycerides. These findings support alcohol reduction as a potentially beneficial lifestyle intervention for improving cardiometabolic profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureBlood GlucoseAlcohol DrinkingLipidsHumansFemaleMaleMiddle AgedTriglyceridesAdultJapan

Stichwörter der Autor:innen

alcohol reductionblood pressurecardiometabolic healthlipid metabolism

Substanzen

Blood GlucoseLipidsTriglycerides

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
  • Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi, Japan.
  • Department of Surgery, Harvard Medical School, Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Orthopaedic Surgery, Matsushita Memorial Hospital, Moriguchi, Japan.
  • Department of Health Care Center, Panasonic Health Insurance Organization, Moriguchi, Japan.

ORCID-Profile: Takahiro Ichikawa, Hiroshi Okada, Shinta Yamamoto, Hanako Nakajima, Masahide Hamaguchi

Förderung

  • Novo Nordisk Pharma Ltd.

Zitieren

APA

Ichikawa, T., Okada, H., Yamamoto, S., Sano, A., Hashimoto, Y., Kasahara, K., Nakajima, H., Hamaguchi, M., Murata, H., Kurogi, K., Tsuda, E., Yoshida, N., Ito, M., & Fukui, M. (2026). Alcohol Reduction and 15‐Year Cardiometabolic Changes in Glycemic, Lipid and Blood Pressure Profiles: A Target Trial Emulation Study. Diabetes, Obesity and Metabolism, 28(12), 11259-11269. https://doi.org/10.1111/dom.71335

Vancouver

Ichikawa T, Okada H, Yamamoto S, Sano A, Hashimoto Y, Kasahara K, et al. Alcohol Reduction and 15‐Year Cardiometabolic Changes in Glycemic, Lipid and Blood Pressure Profiles: A Target Trial Emulation Study. Diabetes, Obesity and Metabolism. 2026;28(12):11259-11269. doi:10.1111/dom.71335

BibTeX
@article{Ichikawa2026,
  author = {Ichikawa, Takahiro and Okada, Hiroshi and Yamamoto, Shinta and Sano, Arata and Hashimoto, Yoshitaka and Kasahara, Kenya and Nakajima, Hanako and Hamaguchi, Masahide and Murata, Hiroaki and Kurogi, Kazushiro and Tsuda, Eri and Yoshida, Naoki and Ito, Masato and Fukui, Michiaki},
  title = {Alcohol Reduction and 15‐Year Cardiometabolic Changes in Glycemic, Lipid and Blood Pressure Profiles: A Target Trial Emulation Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11259--11269},
  doi = {10.1111/dom.71335}
}
Kostenlos starten →